A new drug developed by Tel Aviv University researchers has been licensed by pharmaceutical company BioLineRx and offers a new treatment option to patients with neuropathic pain.
Developed by Bernard Attali and Asher Peretz, MD, of the Sackler Faculty of Medicine, the medication, known as BL-7050, inhibits the transmission of pain signals throughout the body. In experiments measuring electrical activity of neurons, the drug has been shown to prevent the hyper-excitability of neurons, protecting against neuropathic pain and epileptic seizures.
Wisconsin to Have Statewide Drug Monitoring System
Most Patients Take Incorrect Dosages of Prescription Drugs
Developed by Bernard Attali and Asher Peretz, MD, of the Sackler Faculty of Medicine, the medication, known as BL-7050, inhibits the transmission of pain signals throughout the body. In experiments measuring electrical activity of neurons, the drug has been shown to prevent the hyper-excitability of neurons, protecting against neuropathic pain and epileptic seizures.
Related Articles on Pain Management:
Study Sheds Doubt on Steroid Injections for Back PainWisconsin to Have Statewide Drug Monitoring System
Most Patients Take Incorrect Dosages of Prescription Drugs